D&D Pharmatech enters Phase 2 trials for MASH
The company develops peptide therapeutics for metabolic disorders and fibrosis using proprietary delivery technologies. The lead candidate is in Phase 2 for treating metabolic dysfunction-associated steatohepatitis.
- Field
- drugs and trials
- What they did
- D&D Pharmatech has advanced its liver fibrosis drug to the clinical trial phase scheduled for 2027.
- Why it matters
- This will help people with liver fibrosis, as the drug is designed to treat chronic conditions involving fat accumulation and tissue scarring.
#liver fibrosis#peptide therapeutics#mash#phase 2


